SI1414816T1 - Stabilni polimorf filbanserina, tehnični postopek za njegovo pripravo in njegova uporaba za pripravo zdravil - Google Patents
Stabilni polimorf filbanserina, tehnični postopek za njegovo pripravo in njegova uporaba za pripravo zdravilInfo
- Publication number
- SI1414816T1 SI1414816T1 SI200230104T SI200230104T SI1414816T1 SI 1414816 T1 SI1414816 T1 SI 1414816T1 SI 200230104 T SI200230104 T SI 200230104T SI 200230104 T SI200230104 T SI 200230104T SI 1414816 T1 SI1414816 T1 SI 1414816T1
- Authority
- SI
- Slovenia
- Prior art keywords
- flibanserin
- preparation
- technical process
- preparing medicaments
- stable polymorph
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01118593 | 2001-08-02 | ||
EP01130180 | 2001-12-19 | ||
EP02767277A EP1414816B1 (en) | 2001-08-02 | 2002-07-30 | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments |
PCT/EP2002/008466 WO2003014079A1 (en) | 2001-08-02 | 2002-07-30 | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1414816T1 true SI1414816T1 (sl) | 2005-06-30 |
Family
ID=26076670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200230104T SI1414816T1 (sl) | 2001-08-02 | 2002-07-30 | Stabilni polimorf filbanserina, tehnični postopek za njegovo pripravo in njegova uporaba za pripravo zdravil |
Country Status (27)
Country | Link |
---|---|
EP (2) | EP1414816B1 (sl) |
JP (1) | JP3822601B2 (sl) |
KR (1) | KR100899297B1 (sl) |
CN (1) | CN1288147C (sl) |
AR (2) | AR036208A1 (sl) |
AT (1) | ATE288911T1 (sl) |
AU (1) | AU2002331361B2 (sl) |
BR (1) | BR0211601A (sl) |
CA (1) | CA2450093C (sl) |
CO (1) | CO5560572A2 (sl) |
DE (1) | DE60202958T2 (sl) |
DK (1) | DK1414816T3 (sl) |
EA (1) | EA006400B1 (sl) |
ES (1) | ES2237694T3 (sl) |
HK (1) | HK1070063A1 (sl) |
HR (1) | HRP20040107B1 (sl) |
HU (1) | HU228666B1 (sl) |
IL (2) | IL159151A0 (sl) |
MX (1) | MXPA04000913A (sl) |
MY (1) | MY127294A (sl) |
NZ (1) | NZ530510A (sl) |
PL (1) | PL210224B1 (sl) |
PT (1) | PT1414816E (sl) |
RS (1) | RS50742B (sl) |
SI (1) | SI1414816T1 (sl) |
UA (1) | UA76767C2 (sl) |
WO (1) | WO2003014079A1 (sl) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
DE10138273A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Arzneimittel mit neuroprotektiver Wirkung |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
WO2003097058A1 (en) * | 2002-05-22 | 2003-11-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New pharmaceutical compositions containing flibanserin polymorph a |
WO2006119884A2 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
JP2009513604A (ja) | 2005-10-29 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体 |
US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
CA2642368A1 (en) * | 2006-02-28 | 2007-09-07 | Boehringer Ingelheim International Gmbh | Treatment of prevention of valvular heart disease with flibanserin |
RS54398B1 (en) * | 2006-05-09 | 2016-04-28 | Sprout Pharmaceuticals, Inc. | THE USE OF FLIBANSERINE FOR THE TREATMENT OF SEXUAL DESIRE DISORDERS IN POSTMENOPAUSE |
JP2009541443A (ja) | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁及び関連疾患の治療のためのフリバンセリン |
KR20090042967A (ko) | 2006-08-14 | 2009-05-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 플리반세린 제형 및 이의 제조방법 |
CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
EA200900270A1 (ru) | 2006-08-25 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Системы регулируемого высвобождения и способ их приготовления |
WO2008061966A2 (en) * | 2006-11-22 | 2008-05-29 | Boehringer Ingelheim International Gmbh | New use of flibanserin |
JP2010513390A (ja) | 2006-12-20 | 2010-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 混合セロトニン受容体親和性を有する硫酸化ベンズイミダゾロン誘導体 |
EP1955699A1 (en) * | 2007-02-08 | 2008-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Use of flibanserin for the treatment of insomnia |
UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
EP2090297A1 (en) | 2008-02-13 | 2009-08-19 | Boehringer Ingelheim International GmbH | Formulations of flibanserin |
CA2686480A1 (en) * | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
CN104926734B (zh) * | 2015-07-07 | 2017-04-05 | 苏州立新制药有限公司 | 氟班色林的制备方法 |
WO2017076356A1 (zh) * | 2015-11-05 | 2017-05-11 | 苏州晶云药物科技有限公司 | 氟班色林的新晶型及其制备方法 |
CN113683570A (zh) * | 2016-01-31 | 2021-11-23 | 孟晓明 | 氟班色林的新晶型及其制备方法及其用途 |
CN111303043A (zh) * | 2019-04-19 | 2020-06-19 | 武汉万知化工医药有限公司 | 一种氟班色林盐酸盐的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
-
2002
- 2002-07-30 AU AU2002331361A patent/AU2002331361B2/en not_active Expired
- 2002-07-30 UA UA2004031505A patent/UA76767C2/uk unknown
- 2002-07-30 EP EP02767277A patent/EP1414816B1/en not_active Expired - Lifetime
- 2002-07-30 PL PL364598A patent/PL210224B1/pl unknown
- 2002-07-30 RS YUP-78/04A patent/RS50742B/sr unknown
- 2002-07-30 HU HU0401201A patent/HU228666B1/hu unknown
- 2002-07-30 CA CA002450093A patent/CA2450093C/en not_active Expired - Fee Related
- 2002-07-30 DK DK02767277T patent/DK1414816T3/da active
- 2002-07-30 PT PT02767277T patent/PT1414816E/pt unknown
- 2002-07-30 SI SI200230104T patent/SI1414816T1/sl unknown
- 2002-07-30 MX MXPA04000913A patent/MXPA04000913A/es active IP Right Grant
- 2002-07-30 AT AT02767277T patent/ATE288911T1/de active
- 2002-07-30 NZ NZ530510A patent/NZ530510A/en not_active IP Right Cessation
- 2002-07-30 WO PCT/EP2002/008466 patent/WO2003014079A1/en active IP Right Grant
- 2002-07-30 CN CNB028152263A patent/CN1288147C/zh not_active Expired - Fee Related
- 2002-07-30 ES ES02767277T patent/ES2237694T3/es not_active Expired - Lifetime
- 2002-07-30 IL IL15915102A patent/IL159151A0/xx unknown
- 2002-07-30 BR BR0211601-4A patent/BR0211601A/pt not_active Application Discontinuation
- 2002-07-30 EP EP04026410A patent/EP1518858A1/en not_active Withdrawn
- 2002-07-30 KR KR1020047001497A patent/KR100899297B1/ko active IP Right Grant
- 2002-07-30 EA EA200400252A patent/EA006400B1/ru not_active IP Right Cessation
- 2002-07-30 DE DE60202958T patent/DE60202958T2/de not_active Expired - Lifetime
- 2002-07-30 JP JP2003519029A patent/JP3822601B2/ja not_active Expired - Fee Related
- 2002-07-31 MY MYPI20022876A patent/MY127294A/en unknown
- 2002-08-02 AR ARP020102942A patent/AR036208A1/es not_active Application Discontinuation
-
2003
- 2003-12-02 IL IL159151A patent/IL159151A/en active IP Right Grant
-
2004
- 2004-01-30 HR HR20040107A patent/HRP20040107B1/xx not_active IP Right Cessation
- 2004-02-25 CO CO04016766A patent/CO5560572A2/es unknown
-
2005
- 2005-04-01 HK HK05102726A patent/HK1070063A1/xx not_active IP Right Cessation
-
2010
- 2010-07-15 AR ARP100102577A patent/AR077416A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL159151A0 (en) | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments | |
HK1077832A1 (en) | 17a-ALKYL-17ß-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE FRODUCTION THEREOF, AND USE OF SAID 17a-ALKYL-17ß-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS | |
AU2002365516A1 (en) | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | |
HUP0402264A3 (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof | |
PL396568A1 (pl) | Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postać dawkowania, doustna postać dawkowania, zastosowanie oraz sposób wytwarzania krystalicznego bursztynianu O-demetylo-wenlafaksyny | |
HUP0204226A3 (en) | Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds | |
IL158289A (en) | Mercaptoacetylamide derivatives, a process for their preparation and their use as medicaments for the treatment of hypertension and chf | |
IL204947A0 (en) | Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them | |
TWI345975B (en) | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament | |
HUP0400200A3 (en) | Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof | |
HUP0401747A3 (en) | Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds | |
HUP0301075A3 (en) | Diphenyl ether derivatives, their use for preparation of pharmaceutical compositions and process for preparation the compounds | |
HUP0202233A3 (en) | Derivatives and analogues of galanthamin, their use, pharmaceutical compositions containing them and process for the preparation of them | |
HUP0401369A3 (en) | Pharmaceutical formulation comprising (r)-bicalutamide, process for its preparation and use thereof | |
HUP0500958A3 (en) | 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them, therapeutic use thereof and pharmaceutical compositions containing them | |
HUP0303804A3 (en) | Ligands of the avss6 integrin, process for their preparation, their use and pharmaceutical compositions containing them | |
IL158587A0 (en) | Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof | |
HK1070900A1 (en) | Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds | |
TWI346113B (en) | Stable polymorph of flibanserin, technical process for its preparation and use thereof for preparing medicaments | |
IL152751A0 (en) | Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them | |
IL160606A0 (en) | C2-substituted indan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals | |
HUP0201992A3 (en) | Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing the compounds and their use | |
IL160608A0 (en) | C2-substituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals | |
NO20040403L (no) | Stabil polymorf av flibanserin, teknisk fremgangsmåte for fremstilling derav og anvendelse derav for fremstlling av medikamenter | |
HUP0303482A3 (en) | Mercaptoacetylamide derivatives, process for their preparation and their use and pharmaceutical compositions containing them |